エピソード

  • BMY Today - Aug 13: Merger Talk Fizzles Out

    BMY Today - Aug 13: Merger Talk Fizzles Out
    2026/08/13
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down today’s action for Bristol-Myers Squibb, or BMY for short. Today was a bit of a mixed bag, with the stock finishing in the green, up about 0.83%. Not a huge move, but hey, a win's a win, right?

    So, what’s the scoop? BMY was trading around $64, and it felt like a slow day overall. The volume was pretty standard, nothing crazy. But there was some chatter in the air about merger talks involving AstraZeneca, and honestly, it seems like Wall Street wasn’t buying it. You know how that goes; when rumors fly around, people start reacting. But in this case, it looks like investors just shrugged it off.

    Now, let’s talk about why BMY might be in the spotlight. They’ve got a growth portfolio that’s helping balance out some of the legacy pressures they’ve been facing. That’s a big deal because it shows they’re not just sitting around. They’re working on new stuff to keep the momentum going. But, on the flip side, some reports mentioned that BMY has been underperforming compared to its competitors. That one stung a bit, especially since everyone’s always looking for the next big thing in pharma.

    Oh, and here’s a little nugget for you: Bristol-Myers also made some moves with Atrium Therapeutics, hitting them with a milestone payment of $15 million. So, they’re still making strides in the partnership game, which is always good to see.

    To wrap it up, BMY had a decent day despite the mixed signals from the market and some chatter that didn’t really pan out. Just remember, stocks can be a wild ride, and it’s all about keeping your head in the game and staying informed. This is just for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • BMY Today - Aug 12: Merger Talk Fizzles Out

    BMY Today - Aug 12: Merger Talk Fizzles Out
    2026/08/12
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we're talking about Bristol-Myers Squibb, or BMY for short. So, how’d it go? Well, it was a bit of a snooze fest—BMY barely moved, closing up just a smidge, like 0.44%. Not exactly fireworks, right?

    So, here’s the scoop. There’s been some chatter about a possible merger with AstraZeneca. But honestly, Wall Street isn't buying it. That talk seems to have fizzled out, and investors are feeling a bit skeptical. You know how it goes—when there’s uncertainty, people tend to hit the sell button fast. BMY's stock underperformed compared to its competitors today, which isn’t a great look. It’s like showing up to a party where everyone else is dressed to impress, and you’re in sweats. Yeah, that one stung.

    And get this—Handelsbanken Fonder sold a ton of shares, almost half a million. That’s a pretty big move and probably shook some confidence. On the flip side, Wedge Capital is actually raising their stake in BMY, but that didn’t seem to help the stock much today. It’s like a mixed bag of vibes out there.

    Now, on the horizon, Schrödinger, a company that's been in bed with BMY, just announced a solid Q2 profitability and their stock shot up over 19%. That could mean some good news for BMY down the line, but who knows? The market’s a wild ride.

    So, to wrap it up, BMY had a pretty lackluster day, caught in the crossfire of merger talks that aren’t gaining any traction. It’s definitely a stock to keep an eye on, but remember, this is just for info and entertainment. Always do your own research before making any moves. Catch you later!
    続きを読む 一部表示
    2 分
  • BMY Today - Aug 11: AstraZeneca Merger Talks Fall Through

    BMY Today - Aug 11: AstraZeneca Merger Talks Fall Through
    2026/08/11
    Hey there! It's Joey here, your friendly investor buddy, breaking down what went down today with Bristol-Myers Squibb, or BMY for short. So, today was a bit of a downer for the stock, finishing the day in the red, down about 1.9%.

    Now, let’s get into what happened. BMY’s stock took a hit, and honestly, it wasn’t a great day overall. People were selling off shares, and you could feel the tension in the air. A lot of chatter about the company lately has been focused on those merger talks with AstraZeneca that just flopped. Yeah, that one stung. When big deals don’t pan out, it can really shake investor confidence, and that’s what we saw today.

    So, why did this merger not go through? Well, it seems like the talks just didn’t come together, and that left a lot of folks wondering what’s next for BMY. When you’re expecting big moves and then it just fizzles out, it can leave a sour taste, right? Plus, there’s been some buzz about their upcoming earnings estimates, which are still hanging in the air. Investors are kind of in a holding pattern, waiting for fresh news to sink their teeth into.

    On the other hand, there’s some good stuff happening too! BMY is planning to open a new campus in Houston, which is expected to create nearly 500 jobs. That’s a nice boost for the local economy and shows that BMY is still pushing forward, even if the stock took a dip today.

    So, to wrap it up, BMY had a rough day, mostly due to those busted merger talks with AstraZeneca. But hey, they’ve got some exciting things in the pipeline with job growth in Houston, so it’s not all doom and gloom. Just remember, I’m here to share info and keep it fun, not to give you financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • BMY Today - Aug 10: Houston Campus Announcement

    BMY Today - Aug 10: Houston Campus Announcement
    2026/08/10
    Hey there! It’s Joey here, your friendly longtime investor. Let’s chat about Bristol-Myers Squibb today. Spoiler alert: it was a bit of a red day, barely moving at all. We're talking just a tiny dip of 0.01%. Yeah, that one stung a little.

    So, what happened? BMY's stock didn’t really budge much today. It was like watching paint dry. But here's the kicker: they announced plans for a massive $2.3 billion manufacturing campus in Houston. That’s a big deal! It’s set to bring nearly 500 jobs to the area, which is awesome for the community. But despite the good news, people just weren’t feeling it. Maybe they were too focused on the bigger economic picture or the fact that some analysts think BMY might be a bit overvalued right now.

    Now, why did the stock take this snooze fest? Well, a couple of articles pointed out that while the Houston campus is exciting, there’s chatter around interest rates possibly rising in September. That always makes investors a bit jittery. Plus, some folks are saying BMY isn’t the best pick right now—like that one article calling it overvalued. When people start questioning a stock’s worth, they tend to hit the sell button fast.

    Oh, and just a quick heads-up: with all this talk about interest rates and valuations, it’s something to keep an eye on. The market can change on a dime, and what feels solid today might shift tomorrow.

    Alright, that’s the scoop for today on BMY. Always remember, I’m just here to share some info and have a good chat about the stock world. No financial advice here, just good vibes. Catch you later!
    続きを読む 一部表示
    1 分
  • BMY Today - Aug 09: AstraZeneca Merger Rumor Buzz

    BMY Today - Aug 09: AstraZeneca Merger Rumor Buzz
    2026/08/09
    Hey there! It’s Joey here, your friendly neighborhood investor. Just hanging out, breaking down the day’s action for Bristol-Myers Squibb, or BMY for short. So, today was a bit of a mixed bag, but overall, it was a green day for the stock, up about 0.89%. Not a massive jump, but hey, any gain is a gain, right?

    So, here’s the scoop. BMY saw some decent movement today, trading around $64.72. The buzz? There’s chatter about a possible mega-merger between AstraZeneca and Bristol-Myers Squibb. I mean, that’s a big deal! Rumors like that can definitely get people talking and thinking about the future. That said, today’s trading was pretty steady, with the volume hanging around average levels. Nothing too wild, but definitely enough to keep folks interested.

    Now, why the excitement? Well, merger talks are always a hot topic in the market. If two giants like AstraZeneca and BMY were to team up, it could shake things up in the pharma world. Investors are trying to figure out what that might mean for revenues and earnings down the line. Some folks are likely feeling optimistic, thinking about the potential growth and market power a merger could bring. But, you know how it is—rumors can go either way. Sometimes they lead to great things, and sometimes they just fizzle out.

    Oh, and speaking of the horizon, NewEdge Advisors just picked up a chunk of BMY stock, holding about $13.71 million worth. It’s always interesting to see who’s buying in. It might not mean a ton, but it’s a sign some investors are still feeling confident about the company.

    Alright, that’s the lowdown on BMY today! Just a little friendly reminder—this is all about sharing info and having some fun with the markets. So, keep that in mind as you’re out there navigating your own investing journey. Catch you later, folks!
    続きを読む 一部表示
    2 分
  • BMY Today - Aug 08: AstraZeneca Merger Rumors Buzzing

    BMY Today - Aug 08: AstraZeneca Merger Rumors Buzzing
    2026/08/08
    Hey there, it’s Joey! I’ve been investing for years, and today we’re talking about Bristol-Myers Squibb, or BMY for short. It was a bit of a green day, up about 0.89%. Not a huge jump, but hey, we’ll take it!

    So, what went down? BMY was trading pretty steady, but it grabbed some attention today. The buzz mainly came from rumors about a potential merger with AstraZeneca. Yeah, you heard that right! People started speculating about a $400 billion deal, which definitely got investors thinking. Whenever there’s merger talk, you know folks get a little excited.

    Now, why the hype? Well, when two big players like AstraZeneca and Bristol-Myers Squibb are in the same conversation, it’s a big deal. Mergers can shake up the whole market, and investors love to jump on those kind of stories. Plus, there was some chatter about BMY’s partnership with Schrödinger and their AI stuff, which could change the game for them. But honestly, the merger rumors were probably the main driver for today’s action.

    Also, just a heads-up—BMY’s been getting some love from advisory groups lately. MRA Advisory Group picked up over 23,000 shares, and Rockland Trust threw in around $8.47 million. So, there’s some institutional interest brewing, which can sometimes help boost confidence in a stock.

    To wrap it up, BMY had a decent day, mostly thanks to those merger rumors with AstraZeneca. It’s always fun to see how these big stories can shift the market, even if it’s just chatter. Remember, I’m just here to share what’s happening, not to give any financial advice. Keep it chill and happy investing!
    続きを読む 一部表示
    2 分
  • BMY Today - Aug 07: Czech Bank Buys Shares

    BMY Today - Aug 07: Czech Bank Buys Shares
    2026/08/07
    Hey there! I’m Joey, your friendly neighborhood investor, and today I’m breaking down Bristol-Myers Squibb, or BMY. It was a pretty chill day, barely moving, up just a smidge, like 0.27%.

    So, what happened? Well, BMY didn't see any wild swings today. It kind of just hung around the same spot. Volume was right on point with the average, so not much frenzy there.

    Now, why did it move like that? There’s a couple of things to chew on. First off, the Czech National Bank scooped up over 26,000 shares of BMY. That’s a nice little vote of confidence, right? It’s always nice when big players show interest. Also, there’s chatter about a partnership with Schrödinger, which could shake things up for BMY down the line. If that AI magic works out, it could lead to some exciting developments.

    But yeah, the market overall was kind of mixed today, and that can make stocks like BMY move in a more subdued way. Nobody really knows why it didn’t pop more, but that's just how it goes sometimes.

    One thing worth keeping an eye on: the biotech scene is buzzing with potential new drugs that could really change the game for companies like Bristol-Myers. So, even if today was a snooze, there’s always something brewing in the background.

    That’s a wrap for today! Just remember, I’m here to share info and keep it fun, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • BMY Today - Aug 06: Mixed Signals in Pharma World

    BMY Today - Aug 06: Mixed Signals in Pharma World
    2026/08/06
    Hey there! It’s Joey here, your friendly investor, breaking down the day for you. Today, we’re chatting about Bristol-Myers Squibb, and guess what? It was a bit of a mixed bag today, barely moving, just up 0.3%.

    So, what happened? The stock kinda floated around, not making any big waves. People traded about the same amount as usual, and it didn’t really get smoked or skyrocketed. Just a slow day at the office for BMY.

    Now, why the chill vibes? Well, there’s a lot of chatter in the pharma world. I mean, AstraZeneca was in the spotlight today, with rumors flying around about them possibly merging with BMY. But hold up! AstraZeneca shot those rumors down, saying there’s nothing cooking there. So, that probably kept folks on their toes. Plus, there’s been talk about how analysts think BMY is a "moderate buy," but some reports are saying it’s still overvalued. Like, one source even gave it a score of 71 out of 100, which doesn’t scream “buy me!”

    And then we had BMY’s Q2 earnings call recently, where analysts were throwing questions around. It seems like there’s a bit of a mixed signal coming from there too, with some analysts feeling bullish and others a bit more cautious. That uncertainty might've made investors a little jittery today, hence the flat movement.

    One thing worth keeping an eye on? Analysts are still watching the market closely, especially around BMY’s upcoming drug launches and how they’re gonna play out. That could shake things up in the future.

    Alright, that’s the scoop for today! Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分